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Herpesviruses are ubiquitous in animals and cause economic losses concomitant with 
many diseases, including upper respiratory disease, keratitis, abortion, neonatal death, and 
neurologic disease. The majority of the domestic animal herpesviruses are within the subfamily 
Alphaherpesvirinae, along with the prototypical human herpes simplex virus 1 (HSV-1). 
Suppression of HSV-1 replication has been reported with α-hydroxytropolones (αHTs), which 
are aromatic ring compounds that have broad bioactivity due to potent chelating activity. It is 
postulated that αHTs inhibit enzymes within the nucleotidyltransferase superfamily (NTS), 
similarly structured enzymes that require divalent cations for nucleic acid cleavage activity. One 
potential herpesviral target includes the nuclease of the viral terminase, a highly conserved NTS-
like enzyme that cleaves the viral genome for packaging into capsids. Inhibition of the nuclease 
activity of the viral terminase (pUL15C) by αHTs previously revealed variable potencies, ranging 
from negligible to marked. Interestingly, the most potent anti-terminase nuclease αHT 
compounds had limited effect on inhibiting HSV-1 replication. The aim of this study was to 
evaluate three different αHT molecules with varying in vitro anti-terminase nuclease activity 
against veterinary herpesviruses (BoHV-1, EHV-1, FHV-1) and HSV-1 to assess for broad 
inhibitory activity. Additionally, given the discordant potencies between anti-pUL15C and HSV-
1 inhibition, a second objective was to elucidate the mechanism of action of these compounds. 
The results of this research show that αHTs broadly inhibit herpesviruses, with similar inhibitory 
effect among HSV-1, BoHV-1, EHV-1, and FHV-1 with IC50 values ranging from 30 to ≤ 5 μM. 
Based on immunoblotting, Southern blotting, and real-time qPCR, the compounds were found to 




CHAPTER 1: INTRODUCTION 
The family Herpesviridae is composed of double stranded DNA (dsDNA) viruses that are 
both disseminated in the environment and cause disease in an array of vertebrate and invertebrate 
hosts. The ubiquity of herpesviruses is largely due to their ability to undergo both a lytic and 
latent replicative cycle, as latency allows for recurrent infections and transmission. Additionally, 
some herpesviruses have adapted mechanisms of immune evasion, including the production of 
homologs to chemokines and ability to spread among contiguous cells without exposure to 
extracellular antibody [1-3]. These features of latency and immune evasion largely explain the 
high morbidity of herpesviral infections.  
The family is subdivided into three subfamilies based on cytotropism, replication properties, 
and cytopathogenicity and includes Alphaherpesvirinae, Betaherpesvirinae and 
Gammaherpesvirinae. Alphaherpesviruses have short replicative cycles, grow rapidly in cell 
culture, and are neurotropic and cytopathogenic. Important human and veterinary 
alphaherpesviruses include human simplex virus 1 (HSV-1), bovine herpesviruses 1 (BoHV-1), 
equine herpesvirus 1 (EHV-1), and feline herpesvirus 1 (FHV-1).  Betaherpesviruses cause 
cytomegaly and have limited host ranges. These viruses are myelotropic with protracted 
replication and infection, and examples include human cytomegalovirus (HCMV) and suid 
herpesvirus 2 [4, 5]. Lastly, the gammaherpesviruses exhibit tropism for lymphocytes with 
variable replicative rates. The gammaherpesviruses have oncogenic potential, as observed with 
the development of lymphoma in humans infected with human Epstein–Barr virus. Veterinary 
gammaherpesviruses include bovine herpesvirus 4 and equine herpesvirus 2. Interestingly, there 
are also a few reports of oncogenic gammaherpesviruses in animals [6-8].  
2 
 
From a veterinary perspective, herpesviruses are a major cause of morbidity, mortality, and 
economic losses in domestic animal species. Both BoHV-1 and EHV-1 are geographically 
widespread and have high morbidity in outbreak situations. Major economic losses from both 
viruses are due to abortions and poor performance  in racing horses, and poor growth and milk 
production in feedlot cattle, and dairy cattle, respectively [9, 10]. The effects of herpesviruses 
extend into companion animals, as FHV-1 has close to 100% morbidity in felids, particularly in 
shelter or cattery populations. Persistent infections and recrudescence of disease are common in 
cats, and management and treatment of severe disease may be costly [11]. Management of 
veterinary herpesviral infection relies heavily on prevention and control through vaccination, 
quarantining, and population separation based on disease risk [12]. The efficacy of anti-
herpesviral drugs in large animals remains undetermined [13-15]. However, clinical trials 
assessing the efficacy of oral and ophthalmologic anti-herpesviral therapeutics in cats with FHV-
1 revealed improved clinical signs with limited adverse effects [11, 16-18].     
BoHV-1 is also known as infectious bovine rhinotracheitis or infectious pustular 
vulvuovaginitis virus and is a geographically widespread cause of respiratory disease, 
conjunctivitis, genital lesions, and abortion in the cattle industry. Clinical signs include pyrexia 
and mucopurulent oculonasal discharge, often with minimal to marked fibrinonecrotic tracheitis. 
Secondary bacterial infections are common, leading to bronchopneumonia and an increased 
severity of disease [19]. The virus has a wide host range, infecting cattle, sheep, goats, llamas, 
swine, and rabbits; however, clinical disease has only been reported in cattle [4]. BoHV-1 is 
transmitted from (sub)clinically infected cattle or reservoir hosts by aerosolization, contact with 
mucosal secretions, or indirect contact with fomites. Clinical disease is caused by lytic infection, 
and as with other alphaherpesviruses, latency can be established in sensory ganglia [4]. 
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Reactivation of BoHV-1 is common in livestock and can be induced by  endogenous 
corticosteroids secondary to the stress of high stocking densities, transport, pregnancy, poor 
management or diet, or secondary infections [20].  
EHV-1 is widely prevalent, primarily causing sporadic or epizootic abortions and neonatal 
death, upper respiratory tract infections and neurological disease [12]. Viremia depends on the 
strain of the virus and prior exposure of the host [4]. Two strains of EHV-1 have been described 
and include the low (V592) and high (Ab4) virulence strains. V592 is commonly associated with 
abortion, while Ab4 causes neurologic disease. Although there are marked differences in their 
clinical presentation, the nucleotide variation rate between these two strains is only 0.1%. One 
important difference between the two strains is a single nucleotide polymorphism in the viral 
DNA polymerase. A substitution of aspargine (N) to aspartic acid (D) at amino acid position 752 
is associated with neuropathogenicity [10, 21, 22]. Aerosolization, ingestion of abortive material, 
and exposure via fomites are common modes of transmission.  The virus invades the epithelial 
mucosa and infects T-lymphocytes, leading to viremia and widespread endothelial infection. 
Vascular changes, such as vasculitis, thrombosis, and ischemia, are common. In fact, the 
pathogenesis of abortion is initiated by these vascular changes, as thrombosis of vessels within 
the endometrium ultimately leads to infiltration and spread of the virus transplacentally to the 
fetus. The majority of abortions caused by EHV-1 occur in the last three months of gestation. 
Viable foals infected in utero usually develop pneumonia, septicemia, and/or encephalitis with 
eventual death [23].  
FHV-1 is a major cause of feline morbidity with an overall low mortality rate. Although all 
felid species are susceptible, the disease is particularly widespread in domestic cats due to the 
prominence of multi-cat households and animal shelters. FHV-1 manifests as rhinotracheitis, 
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conjunctivitis, and ulcerative keratitis; other less common diseases include ulcerative dermatitis 
and stomatitis, abortion, pneumonia, vasculitis, and multi-organ hemorrhage [24]. In naïve 
animals, the disease is usually self-limiting; however, lifelong latency with eventual 
recrudescence of respiratory disease is common. The virus is transmitted through direct contact 
or aerosolization, allowing invasion of mucosal epithelial cells and eventual lytic replication. 
Target tissues include the cornea and conjunctival epithelium, due to ideal lower body 
temperature at these sites.  Systemic infection from macrophagic spread to nodal or other target 
tissues is rare [4].  
In addition to their veterinary importance, human herpesviral infections are considered a 
worldwide pandemic, and the prevalence is increasing [25]. Approximately 90% of the human 
population is known to be infected with a herpesvirus [26]. Diseases in people with HSV-1 range 
from mucocutaneous ulcers to blindness and fatal encephalitis, and this range of disease depends 
largely on immune status. Transmission is through direct contact; as with other herpesviruses, 
the infection is lifelong and often establishes latency. Current anti-herpesviral treatment aims at 
controlling infections but does not prevent future outbreaks, and most treatments target the viral 
DNA polymerase [27]. Additionally, drug-resistant herpesviruses are frequently encountered 
clinically, particularly among immunocompromised patients [28]. Prevention through vaccine 
development would ideally control the infection rate. Despite many attempts, however, an 
effective vaccine has yet to be developed [29]. Thus, there is a great need for novel anti-
herpesviral compounds, which ultimately requires an understanding of the viral life cycle.  
The herpesvirus virion contains linear dsDNA within the core, which is surrounded by the 
capsid, tegument, and envelope. Viral entry is initiated through the interaction of surface 
envelope glycoproteins with cell glycosaminoglycans [30, 31]. The viral envelope fuses with the 
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host cell membrane, allowing for internalization of the nucleocapsid, which is then transported to 
nuclear pores by way of microtubular transport.  Because the DNA is packaged through a 
pressurized, ATP-dependent system, destabilization of the capsid by interaction with the nuclear 
pore complex causes viral DNA to be injected through the nuclear pore into the nucleoplasm.  
The viral DNA then circularizes and viral transcripts are generated by cellular RNA polymerase 
II, beginning  with transcription of the α (immediate-early) genes. The α proteins derived from 
translation of these mRNAs then activate β (delayed-early) gene transcription, the products of 
which are important for DNA replication. Replication of the viral genome occurs through the 
formation of the replication complex, which is composed of viral DNA polymerase and its 
processivity subunit, three components of the helicase-primase complex, and single-stranded 
DNA binding protein [32]. The viral genome is replicated by the rolling circle mechanism, 
producing a concatemer of DNA that must be cleaved into monomers for packaging into capsids. 
Cleavage of the concatemeric DNA is proposed to occur through a triplex of proteins, termed the 
viral terminase. DNA synthesis activates γ (late) gene transcription, involved in capsid 
production and virion assembly. The filled capsid obtains an envelope by budding from a cellular 
membrane and egresses out of the cell [32]. 
Herpesviruses contain many well-conserved enzymes within the nucleotidyltransferase 
superfamily (NTS), which are enzymes with a similar structure and function that have a 
ribonuclease H (RNase H)-like fold. RNase H functions to cleave the phosphodiester bonds of 
RNA that is hybridized to DNA, and examples include the HIV RNase H and HIV integrase [33-
36]. In HSV-1, enzymes with similar RNase H-like activity include the single-stranded DNA 
binding protein, alkaline nuclease, DNA polymerase, and terminase [37-42]. Given the enzymes’ 
similar structure, inhibitors of the HIV RNase and integrase were recently screened for activity 
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against HSV-1 and HSV-2 [43]. The classes of inhibitors included tropolones, polyoxygenated 
heterocyles, and hydroxyxanthenones. Tropolones, including natural and synthetic α-
hydroxytropolones (αHTs), were found to be potent anti-HSV inhibitors [43, 44]. To further 
investigate their HSV-1 inhibitory activity, synthetic αHTs were shown to target the nuclease 
domain of the viral terminase in vitro, suggesting anti-cleavage activity [45]. Interestingly, some 
of the most potent anti-terminase synthetic αHTs exhibited fair to poor HSV-1 replication 
inhibition, while αHTs that exhibited excellent HSV-1 replication inhibition had poor anti-
terminase activity [44, 45].  
The aim of this research included testing the activity of three αHTs with varying anti-HSV 
and in vitro anti-terminase potency to important veterinary herpesviruses, including BoHV-1, 
EHV-1, and FHV-1. Additionally, further exploration into the mechanism of action of αHTs was 
assessed using HSV-1. The goal was to establish that αHTs have broad herpesviral inhibitory 
activity at non-toxic concentrations and may serve as a potential veterinary and medical anti-




CHAPTER 2: LITERATURE REVIEW 
2.1. Herpesviridae 
2.1.1. The Virion  
 The fully mature and enveloped virion is the infectious form of a virus. Members of the 
Herpesviridae family share a common structure of the virion, and virion architecture is 
considered a criterion for inclusion into the family. The virion is spherical and ~200 nm in 
diameter, though the size varies among species. The core contains a single copy of linear dsDNA 
and is surrounded by a capsid, tegument, and lipid envelope. The ~125 nm icosahedral capsid is 
composed of two shells, consisting of 11 different proteins [46]. A single unique vertex, the  
portal complex, breaks the symmetry of the icosahedral capsid and is important for DNA 
packaging [47]. Surrounding the capsid is the proteinaceous tegument, which is important in 
modulating the host antiviral response and initiating viral transcription. Although mostly 
unstructured, the tegument exhibits polarity and contains virally encoded proteins. The lipid 
envelope is studded with glycoproteins, important for viral entry, and is derived  from host 
cytoplasmic membranes [32, 48].   
2.1.1.a. The Core and Viral Genome 
 As the nonchromatinized dsDNA viral genome is large at 125-240 kbp, packaging into 
the core requires order. The exact arrangement of the viral genome within the capsid has not 
been elucidated; however, the viral genome is densely accumulated with ~2.6 nm spacing and 
extends to the inner layer of the capsid shell [49]. Two polyamines, spermine and spermidine, are 
found in high amounts in the herpesviral capsid and are thought to counteract the strong 
repulsive forces of the negatively charged phosphate backbone, particularly important as 
herpesviruses are devoid of histones [50].  
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 The herpesviral genomes are markedly variable and differ in size (125-240 kbp), 
composition (classes A-E), and G+C content (32-75%), depending on the species (Table 1). 
However, all herpesviral genomes contain direct or inverted repeats that are involved in 
intramolecular recombination and encompass the immediate-early genes, packaging signals, and 
the promoter for latency-associated transcript RNAs [51]. There are five genomic classes, 
labeled A, B, C, D, and E. Herpesviruses within the Varicellovirus genus, including BoHV-1, 
EHV-1, and FHV-1, fall into Class D. Genus Simplexivirus, including HSV-1, has the most 
complex genomic structure, characterized by class E (Table 1). Both classes D and E contain two 
unique sequences, a long and short sequence (UL and US, respectively). In class D, the US 
segment is flanked by a repeated terminal sequence with an internal inverted sequence, 
producing two isomers that differ usually only by the orientation of the US [51]. Class E is 
similar; however, four genomic isomers can be generated, as both the UL and US segments are 
bracketed by terminal repeats with internal inversions, represented by ab-UL-b’a’c’-US-ca [32].  
 
 
Table 1. Genus, Species, and Genome Properties of Applicable α-Herpesviruses 











Simplexvirus HSV-1 E 152 68 84 [52, 53] 
Varicellovirus 
BoHV-1 D 136 72 73 [54, 55] 
EHV-1 D 150 56 76 [23, 56] 





Conserved across the three subfamilies of Herpesviridae are 41 core genes, which can be 
further grouped into 6 gene blocks based on gene order and polarity. Included in the list are those 
genes required for DNA replication (e.g., helicase/primase complex, DNA polymerase, single 
stranded DNA binding protein) and packaging (e.g., terminase binding protein, terminase 
complex). The majority of genes within subfamilies are homologous; however, minor 
discrepancies have been documented, as with BoHV-1 and HSV-1 [54, 58]. As HSV-1 is the 
prototypical herpesvirus, HSV-1 gene and protein names will be used, and the analogous 
counterparts of the veterinary herpesviruses will be detailed in Table 2.  
 















































































































Reference NC_001806.2 [54, 55] [56] NC_013590.2 
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2.1.1.b. The Capsid 
 The architecture and assembly process of the two-shelled capsid is comparable among 
Herpesviridae. The outer component of the capsid is composed of 955 copies of major capsid 
protein, which forms 150 hexons and 11 pentons [46, 59]. In HSV-1, the major capsid protein is 
VP5, which is encoded by UL19.  Each hexon contains six molecules of VP5 and six molecules 
of the “ring” protein, VP26, creating the twenty sides of the icosahedron. The function of VP26 
has not fully been elucidated; it has been suggested this protein helps to link the capsid and 
tegument [60]. Each penton is made up of five copies of VP5, forming 11 of the 12 vertices of 
the icosahedron. Linking the pentons and hexons in groups of three are the triplex proteins, 
composed of two molecules of VP23 and one molecule of VP19C [61]. The last vertex is 
composed of the portal complex, a cylindrical structure composed of 12 copies of pUL6, which is 
important for DNA transport. Structural analysis has shown that the portal is 16.5 nm in diameter 
and 9 nm in length and is markedly similar to the portal vertex in bacteriophages [62]. The inner 
portion of the capsid contains over 1,000 copies of scaffold proteins [46]. Although encoding 
genes and proteins are likely different, capsid architecture is likely similar with other 
herpesviruses.  
2.1.2. Viral Gene Expression and DNA Replication  
 Herpesviral genes can be divided into three groups, immediate-early (α), early (β), and 
late (γ), based on temporal properties and dependency on protein synthesis. The α genes are 
expressed independently of protein synthesis, and their products are necessary for synthesis of 
the β and γ proteins. Synthesis of α proteins peak 2 to 4 hours post-infection. Transcription of the 
β genes requires the presence of two of the five α proteins. β proteins peak 5 to 7 hours post-
infection and include the enzymes necessary for DNA replication. Viral DNA replication occurs 
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shortly after β gene transcription, detectable 3 to 15 hours post infection. The γ genes produce 
structural proteins for progeny and their optimal transcription is dependent on DNA synthesis 
[37].  
In HSV-1, α gene de-repression occurs through the interaction of tegument protein VP16, 
host cell factor 1 (HCF-1), octamer-binding protein 1 (Oct-1), and lysine-specific demethylase 1 
(LSD1). Upon release from the tegument, VP16 binds to HCF-1, a regulatory cell cycle host 
protein. In the nucleus, the VP16-HCF-1 complex binds to Oct 1, which recognizes a consensus 
sequence called the octamer motif in viral DNA. Interestingly, the octamer motif is present in 
both cellular and viral enhancers. To ensure specificity of VP16-HCF-1 complex binding to the 
viral enhancer, a conformational change ensues when Oct-1 binds to GARAT elements, 
sequences present in the viral enhancer.  Lastly, LSD1 recruitment to the complex ultimately 
results in demethylation of an inhibitor present on the α promoter, allowing α gene transcription 
[63].  Thus, these four molecules form a complex that de-represses immediate-early promoters 
and initiates transcription of the five immediate-early genes (i.e., α4, α27, α47, α0, and α22).  
 The broad functions of the α proteins are two-fold, triggering expression of β genes and 
providing negative feedback on α gene expression. Important α proteins include α4 protein 
(ICP4), α0 protein (ICP0), and α27 protein (ICP27).  ICP4 interacts with transcription factors on 
viral promoters for post- α gene transcription and represses its own expression. ICP27 enables β 
protein expression and translation of viral mRNAs, particularly mRNAs of β gene products 
required for DNA synthesis [64, 65]. Lastly, ICP0 is a transcriptional activation protein that 
contains ubiquitin ligase domains, which degrade nuclear proteins required for the formation of 
replication compartments as well as cellular proteins that function in antiviral defense [66, 67].  
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Expression of seven β genes are required for DNA replication, and these genes encode 
viral DNA polymerase (UL30) and the processivity factor (UL42), an ori-binding protein (UL9), 
single-stranded DNA binding protein (UL29), and the heterotrimeric helicase-primase complex 
(UL5, UL8, and UL52). These essential proteins localize to the replication compartments [66]. 
Upon entry into the nucleus, the linear viral dsDNA circularizes, likely through either 
recombination or the activity of DNA ligase IV/XRCC4 which forms endless genomes [37, 68]. 
After circularization, DNA replication likely occurs in two steps: bidirectional theta-type 
replication, which is origin site dependent, followed by a switch to rolling circle replication. The 
mechanism that causes the switch from theta-type to rolling circle replication is currently 
unknown [69].   
HSV-1 contains three origins of DNA replication, oriL located in the UL region and two 
copies of oriS located in the repeat region flanking US. Initiation of theta DNA replication begins 
with ori-binding protein (OBP), a DNA helicase with a C-terminal domain that has sequence-
specific binding to origins of replication. Specifically, OBP recognizes the sequence, 
TTCGCAC, which is highly conserved among alphaherpesviruses [70].  Binding of OBP to the 
ori initiates strand unwinding, which induces the formation of a stable hairpin [70]. Single-
stranded DNA binding protein (ICP8) facilitates OBP by stimulating the helicase activity as well 
as binding preferentially to single-stranded DNA [32, 71]. ICP8 interacts with an alkaline 
nuclease, encoded by UL12, to promote strand exchange and reannealing of complementary 
strands. Both ICP8 and UL12 are predicted to have an RNase-like fold. ICP8 is also involved in 
regulation of γ gene expression [37, 38, 40, 42, 72]. Binding of the OBP and ICP8 to DNA 
recruit the remaining five required β proteins.  
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The replisome includes helicase-primase complex, viral DNA polymerase and its 
processivity protein, and ICP8. The helicase-primase trimer contains the UL5 helicase, the UL52 
primase, and the UL8 accessory protein. The helicase-primase dimer is enzymatically functional 
without the accessory protein, but requires the protein for localization to the nucleus [73]. The 
complex likely unwinds short oligonucleotides annealed to single-stranded DNA. As the enzyme 
has 5’ to 3’ directionality, the complex is likely functional along the lagging strand at the 
replication fork [37]. Viral DNA polymerase is a heterodimer, composed of UL30 enzyme, a 
polymerase with intrinsic 3’ to 5’ exonuclease activity, and the UL42 processivity protein. The 
UL30 polymerase is 25% identical to DNA polymerase δ from Saccharomyces cerevisiae and 
contains three sequence motifs that are homologous to the exonuclease sequences of E. coli 
DNA polymerase [37, 73]. Interestingly, HSV-1 DNA polymerase has also been shown to 
degrade the RNA strand of RNA:DNA hybrid substrates, indicating RNase activity [37, 41]. As 
the name implies, the UL42 processivity protein increases the catalyzing ability of DNA 
polymerase activity. Together, the HSV-1 UL30-UL42 complex exhibits an average elongation 
rate of 44 nucleotides/second [73]. Theta-type replication yields intermediate circular DNA that 
then switches to origin site independent rolling circle replication. Rolling circle replication 
begins with a nick of one of the circular strands. The 3’ end of the nicked strand serves as a 
primer for unidirectional synthesis, using the unnicked strand as a template. Ultimately, 
concatemers of DNA are generated that are cleaved and packaged into capsids.   
Initiation of DNA replication promotes expression of γ genes, and transcription of γ 
genes occurs within the replication compartments. The γ genes encode structural proteins that are 
important for assembly of infectious progeny. There are two classes of γ genes, which are 
separated based on their dependency for DNA synthesis. The γ1 (“leaky-late”) genes are 
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expressed optimally after the onset of DNA synthesis, while expression of the γ2 (“true” late) 
genes require DNA synthesis. The majority of the γ genes encode capsid, tegument, and 
envelope proteins (e.g., UL19, which encodes VP5, and UL25). 
2.1.3. Capsid Assembly  
 Within replication compartments around the time of DNA synthesis, capsid assembly 
occurs. The capsid proteins localize to the nucleus, but the important capsid proteins, VP5, 
VP26, and VP23 are unable to localize to the nucleus individually. VP5 is likely carried to the 
nucleus by interacting with VP22a (ICP35), the major component of the inner shell, in the 
cytoplasm. VP23 requires expression of VP19C in order to enter the nucleus, and lastly, VP26 
migrates to the nucleus only when complexed to VP5-VP19C or VP22a [32]. This strict 
requirement for nuclear entry serves as a control mechanism for capsid assembly. Additionally, 
the binding of VP23 to VP19C ensures the correct number of proteins for triplex formation [46].  
 Capsid assembly begins with the formation of the portal vertex, which is composed of 12 
copies of pUL6. These 12 proteins assemble into a ring, requiring a leucine zipper and disulfide 
bonding for stability [74, 75]. Once the portal vertex is formed, the hexons, pentons, and 
triplexes are added, forming the spherical procapsid. Initiating capsid assembly with the portal 
vertex ensures that each capsid contains the pore, which is essential for production of infectious 
progeny. Capsid maturation is dependent on a protease, located at the N terminus of the scaffold 
protein encoded by UL26. Maturation of the capsid, from a less-stable spherical procapsid to 
icosahedral capsid, begins with cleavage and subsequent activation of the protease. Three types 
of capsids can mature from procapsids, including types A, B, and C, so named based on their 
separation via sucrose gradient centrifugation. Due to an abortive packaging event, A capsids 
lack both the inner scaffold and DNA. A capsids rarely occur in wild-type infections. B capsids 
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resemble procapsids as the scaffold is retained; DNA fails to insert due to defective packaging. 
The B capsids are referred to as dead-end products and represent ~20-30% of capsids seen in 
cells infected with wild-type virus [46]. C capsids contain viral genomes and develop into 
infectious virions [46, 76].  
2.1.4. Encapsidation 
 Encapsidation is the process of insertion and cleavage of concatameric viral DNA into 
unit-length monomers. The process is energy-dependent and requires seven gene products, 
including those of UL6, UL15, UL17, UL25, UL28, UL32, and UL33 [32]. Specifically, the long 
component terminus of the genome is cleaved then inserted into the capsid portal followed by a 
subsequent cleavage event of the short component terminus [32]. A complex of two capsid-
associated proteins have been observed on all mature capsid types. This complex is named the 
capsid vertex-specific complex (CVSC) and contains pUL17 and pUL25 [77]. The function of 
this complex is associated with DNA cleavage and packaging. pUL17 likely allows the capsid to 
be competent for DNA packaging [78]. The function for pUL25 is specific to cleavage of the 
short component terminus, as UL25-null mutants result in normal cleavage of the L terminus with 
a truncated S terminus [76, 79]. Other suggested roles for pUL25 include structural support for 
the capsid or assisting in DNA retention in the capsid [80, 81].  
 The terminase is a multienzyme complex, composed of gene products from UL15, UL28, 
and UL33, and serves as a molecular motor to both drive dsDNA into the capsid and cleave the 
concatamer. Herpesviral terminases are similar to bacteriophage T4 terminases in that one gene 
(UL15) encodes a canonical Walker box, indicative of ATPase activity [46, 82]. The terminase 
must dock to the capsid, presumably adjacent to the portal vertex. dsDNA is pumped into the 
capsid through hydrolysis of ATP and is scanned by the terminase for specific cleavage sites. 
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Recall that the HSV-1 genome falls in the class E category, where both the unique sequences are 
flanked by inverted repeats, represented by ab-UL-b’a’c’-US-ca. The sequences required for 
genome maturation (cis-acting sequences) are present in the a terminal repeat, which contains its 
own unique sequences (Uc and Ub) that are bracketed by a series of direct repeats (DR). The 
signal for cleavage occurs upon terminase recognition of the two packaging sequences, pac1 and 
pac2, which are located within Uc and Ub of the a terminal sequence. The specific site of DNA 
cleavage is within one of the DR regions. The pac1 sequence is specifically recognized by the 
product of UL28, which is bound to UL15 and stabilized by UL33 [83]. The terminase complex 
thus has both DNA-binding and nuclease capacity provided by the functions of pUL28 and 
pUL15, respectively.  
The C-terminal nuclease domain of pUL15 (pUL15C) resembles an RNase H-like domain 
and has recently been crystallized [39]. The crystal structure is packed as a trimer of three 
identical  molecules with a central seven-stranded β-sheet surrounded by six α-helices and four 
loops. Although the amino acid sequence identity is poor between pUL15C and RNase H, the 
structure  of pUL15C is markedly similar and superimposable to enzymes in the NTS. The active 
site is located at the central β-sheet and contains several acidic residues. Consistent with NTS 
enzymes, these residues generate marked negative charges allowing for cation-mediated DNA 
binding and cleavage. As proof of concept, the nuclease activity of pUL15C is potentiated by 
Mg2+ and inhibited by the chelator EDTA [39]. In order to simulate the binding of dsDNA to 
pUL15C, a model was constructed using an RNAse H1 template. Based on this model, the loop 
structures make contact with dsDNA which is reinforced by binding of positively charged 
residues to the DNA phosphate backbone. This binding likely allows for proper orientation of the 
β-sheet active site for cleavage activity [39].  
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Upon binding of dsDNA and recognition of the cleavage signal, the pUL15C component 
of the terminase makes an initial cut in the long terminus followed by subsequent cleavage of the 
short terminus, freeing a monomer of DNA from the concatemer. Viral DNA is then inserted into 
a procapsid through the portal vertex by conversion of chemical energy from ATP hydrolysis 
[32]. As DNA becomes packaged into the procapsid, the internal capsid scaffold is removed and 
the outer shell angularizes from a spherical to icosahedral shape, generating a mature C capsid 
and sealing DNA inside [46, 84]. Envelopment and viral egress follow, resulting in formation of 
infectious viral progeny.  
2.1.5. Differences in BoHV-1 and EHV-1 Virion Structure and Life Cycle 
2.1.5.a. BoHV-1 
The structural composition of the BoHV-1 virion is similar to HSV-1. VP5, which is 
conserved across the alphaherpesviruses, is an essential gene in BoHV-1 and also serves as the 
major capsid protein [54, 85]. The BoHV-1 tegument is composed mostly of VP8 [86].  The 
majority of BoHV-1 genes are homologous to HSV-1; however, there are four unique BoHV-1 
ORFs, Circ, UL0.5, UL3.5, and US1.5 [55]. Three of these unique ORFs are essential in BoHV-1 
[54]. As previously reported in Table 2, many genes encoding important enzymes for DNA 
synthesis and packaging are well-conserved. Transcription of α proteins is also initiated by VP16 
in BoHV-1, but through different cellular targets [87]. There are two origins of replication in 
BoHV-1, which are present within the inverted repeat region of US [54]. DNA replication and 
packaging is largely similar to HSV-1 [88, 89]. 
2.1.5.b. EHV-1 
Five unique genes with no known homologs to other herpesviruses are encoded by the 
EHV-1 genome. These include ORFs 1, 2, 67, 71, and 75; the roles of these genes has yet to be 
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understood [23]. EHV-1 is unique in that the virus encodes only one α gene, ORF 64, which is 
essential for viral replication [90]. The homolog to HSV-1 VP16 is a late protein product of 
ORF12, ETIF, which also serves to transactivate the immediate-early promoter [56, 91]. EHV-1 
possesses three ori, and DNA replication, cleavaging, and packaging are thought to be similar to 
HSV-1 [56].     
2.2. The Pathway to Drug Discovery 
Development of novel therapeutics is expensive and time-consuming, as the process can 
take approximately 10-15 years and cost $800 million to $2 billion [92, 93]. Additionally, the 
process is overwhelmingly inefficient as only 10% of researched drugs become approved by the 
FDA [94]. The traditional approach to drug development is separated into clinical phases. In the 
preclinical phase, the  drug is tested in cell culture and/or animal models to assess biological 
activity and safety. This phase takes an average of 5 years and costs over 100  million dollars,  
with only 5-20 compounds passing to phase 1. A phase 1 clinical trial includes a small number of 
healthy and/or diseased individuals to study the safety and maximum tolerated dose of a 
compound. Phase 2 trials usually have larger numbers of human subjects and are designed to test 
pharmacokinetics and pharmacodynamics. To assess efficacy and further evaluate safety, phase 3 
trials are performed, involving a target population [95]. The three clinical phases each take an 
average of 2 years; cost can vary from $30 to 100 million with the larger, later phases (phase 3) 
being the most expensive. An average of 3 compounds are approved to each subsequent clinical 
phase. Following a successful phase 3 clinical trial, a selected compound is reviewed by the 
FDA. If approval is granted, a fourth confirmatory trial, also called a surveillance study, may be 
mandated by the FDA for a minimum of 2 years or may be requested by the pharmaceutical 
company for further evaluation of pharmacokinetics, efficacy, and safety [93]. 
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2.3. Current and Developing Treatments for Herpesviruses 
2.3.1. Inhibition of DNA Polymerase 
 To date, nearly all anti-herpesviruses available on the market target the viral DNA 
polymerase. The only exception includes fomivirsen, which is an antisense oligonucleotide for 
the treatment of HCMV retinitis [27]. Nucleoside analogues are a specific class of anti-
herpesviral therapy that become incorporated into DNA and thus inhibit DNA replication. Six of 
the nucleoside analogues are guanosine analogues, including acyclovir and ganciclovir. These 
compounds rely on both a viral and host kinase, as two phosphorylation events are required for 
their activation. Their dependency on viral kinases results in varying affinities in different 
herpesvirus systems; for example, acyclovir has a higher affinity for α-herpesviral thymidine 
kinases compared to ganciclovir and is thus a better target for HSV-1 [27]. Viral resistance is a 
major limitation of nucleoside analogues and is frequently caused by acquired mutations in the 
viral thymidine kinase gene and/or mutations in DNA polymerase [96, 97]. Viral resistance 
occurs more often in immunocompromised patients that are on long-term therapy, and cross-
resistance with other kinase-dependent nucleoside analogues often renders this class of 
therapeutics ineffective. Additionally, side effects secondary to long-term use of guanosine 
analogues include nephro- and neurotoxicity and have been linked with inhibition of 
mitochondrial DNA polymerase [98, 99]. Kinase-independent drugs include cidofovir and 
foscarnet. Cidofovir is a cytidine analogue that solely requires host kinases for activation. 
Foscarnet specifically prevents chain elongation of DNA polymerase by binding to the 
pyrophosphate binding site [27]. Although these compounds confer less resistance, both drugs 
must be administered intravenously and are linked with severe adverse effects, like 
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myelosuppression and nephrotoxicity [27]. Due to the rise in viral resistance, development of 
anti-herpetic therapeutics with different mechanisms of action is in dire need.  
2.3.2. Inhibition of Helicase-Primase Complex 
 In 2002, Bayer AG developed pritelivir, a compound that inhibits the helicase primase 
complex. Pritelivir specifically binds both UL5 and UL52, inhibits their respective DNA helicase 
and RNA polymerase activities, and ultimately ceases DNA synthesis. More importantly, this 
compound does not require a phosphorylation activation step by viral or cellular kinases [100]. 
In 2010, the efficacy of pritelivir was assessed in people with genital lesions caused by HSV-2; 
pritelivir reduced both viral shedding time and days with genital lesions. The results were 
confirmed by an additional study in 2013 comparing the effects of pritelivir to valacyclovir, a 
nucleoside analogue and prodrug to acyclovir; pritelivir significantly decreased HSV-2 shedding 
and lesions compared to valacyclovir [101, 102]. A clinical trial evaluating the efficacy of 
pritelivir against HSV-1 is underway (ClinicalTrials.gov Identifier: NCT02871492). More 
recently, another helicase-primase inhibitor known as ASP2151 has been shown to inhibit HSV-
1, HSV-2, and VZV and is more potent than acyclovir [103-105]. Several clinical trials assessing 
ASP2151 in herpesviruses have been completed; results of these studies have yet to be posted 
(ClinicalTrials.gov).  
2.3.3. Inhibition of the Portal Vertex 
A thiourea compound, identified as WAY-150138, is a potent HSV-1 inhibitor that 
inhibits the formation of the portal vertex. In the presence of WAY-150138, viral DNA cleavage 
is blocked with subsequent build-up of B capsids [106]. Escape mutants specifically revealed 
single point mutations in the UL6 gene, and it has been suggested that this compound prevents 
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the incorporation of UL6 into capsids [107]. Current research regarding WAY-150138 is lacking, 
which may be due to the compound’s poor bioavailability [27, 108].  
2.3.4. Inhibition of the Terminase 
Currently,  anti-terminase drugs include a few compounds that inhibit HCMV with 
limited activity against alphaherpesviruses. These compounds are within three classes, 
benzimidazole ribonucleosides (TCRB and BDCRB), sulfonamides (BAY 38-4766), and 
dihydro-quinazolines (Letermovir/AIC246) [27]. Resistance mutants of the benzimidazole 
ribonucleosides and BAY 38-4766 contain mutations in genes that encode  HCMV terminase 
components (UL56 and UL89). Current research regarding these three compounds is lacking. 
However, letermovir has shown promising results against HCMV with an impressive EC50 of 4-5 
nM. Letermovir escape mutants, which have been mapped to pUL56, are susceptible to other 
classes of anti-terminases suggesting a separate mechanism of action [109, 110]. Interestingly, 
this compound was found to be ineffective in vitro for rodent (mouse and guinea pig) 
cytomegalovirus strains [111]. A phase III trial evaluating letermovir for the prevention of 
HCMV has been completed without published results (ClinicalTrials.gov Identifier: 
NCT02137772).  
2.4. Nucleotidyltransferase Superfamily 
The nucleotidyltransferase superfamily is a group of enzymes that share a similar structure 
and function. The enzymes transfer nucleoside monophosphate from nucleoside triphosphate to a 
nucleic acid or protein hydroxyl group, and function in DNA repair, RNA editing and 
polyadenylation, and chromatin remodeling activities [112]. These proteins usually contain a 
central β-sheet surrounded by four α-helices [112].  This conserved motif, particularly near the 
active sites, successfully predicts that these enzymes depend on divalent cations for function [35, 
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39, 113, 114]. Select examples of NTS enzymes include E coli RNase H1 and 2, human RNase 
H1 and 2, human DNA polymerase, HIV RNase H, and HIV integrase [34, 36, 112, 115-118]. 
As previously mentioned, herpesviruses have a few enzymes with RNase H-like folds, including 
ssDNA bp (ICP8), alkaline nuclease, DNA polymerase, and pUL15 of the viral terminase [37-39, 
42]. Development of HIV RNase H and integrase inhibitors has been of recent interest, including 
compounds that interfere with metal chelation of the active site [119-122]. Given the structural 
homology of these enzymes, use of anti-RNase H drugs against herpesviruses has been explored; 
the results of these studies will be discussed in the subsequent section [38, 43-45].  
2.5. Inhibition of HSV-1 by NTS Inhibitors 
Select NTS inhibitors, including compounds within the tropolone, polyoxygenated 
heterocycles, and hydryoxyxanthenone classes, were recently screened against HSV-1, HSV-2, 
HCMV, and acyclovir-resistant mutants of HSV-1 and HSV-2. Several compounds were found 
to inhibit viral replication at low drug concentrations with minimal cytotoxicity; the majority of 
the effective compounds were within the tropolone family, specifically the αHT subclass [64]. 
These tropolones had 50% effective concentration values ranging between 0.35 and 1.94 μM 
against HSV-1 and minimal toxicity [43]. Based on the results of time-to-addition assays, the 
inhibitory effect of one representative αHT compound (β-thujaplicinol) occurred early in viral 
replication as the inhibitory effect decreased when application of the compound was delayed 
beyond 2 hours. To assess whether this class of compounds required viral thymidine kinase 
phosphorylation for activation, β-thujaplicinol was screened against acyclovir-resistant mutants 
of HSV-1 and HSV-2; replication of both strains of mutants was suppressed. These compounds 




αHTs are within the troponoid family, a chemical group of stable non-benzenoid seven-
membered ring compounds that exist in nature (e.g., fungal products, wood of cedar). αHTs have 
been of much historical and recent interest due to their broad bioactivities [123]. The most 
studied αHT, β-thujaplicinol was discovered from the western red cedar tree, Thuja plicata, due 
to its natural fungicidal activity [124]. Aside from antiviral properties, extensive research with 
αHTs has revealed that these compounds also contain antifungal, antibacterial, antimalarial, and 
anticancer properties. The chemical structure of αHTs consists of three oxygen atoms that create 
a potent negative charge at physiological pH, explaining their potent metal chelating ability 
[124].  It has recently become possible to synthesize αHTs with chemical modifications that may 
potentiate their activity or eliminate cytotoxic effects [124].  
2.5.2. Inhibition of HSV-1 by α-Hydroxytropolones 
It is postulated that the inhibitory effect of αHTs on HSV-1 is due to suppression of 
enzymes with RNase H-like domains, particularly through chelation of required divalent cations. 
One possible enzyme in HSV-1 requiring such cations is the nuclease active site of one 
terminase component, pUL15, which is highly conserved among all herpesviruses. To further 
investigate inhibition of the viral terminase, the nuclease activity was assessed in the presence of 
several synthetic β-thujaplicinol derivatives through the analysis of pUL15C-mediated hydrolysis 
of short DNA duplexes using dual-probe fluoresecence [45].  Twenty-one synthetic αHTs with 
different chemical substitutions at positions 3 and/or 4 of the seven-membered ring were 
monitored for pUL15C inhibition. The compounds had variable potencies, with IC50 values 
ranging from 0.14 to 49 μM; compounds with smaller ester and ketone substitutions were more 
potent than those with larger or aromatic modifications [124]. 
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Comparing the in vitro anti-terminase and in vivo anti-HSV activities of synthetic αHTs 
reveals an indirect relationship. The more potent anti-terminase αHTs have poor to fair anti-HSV 
suppression, as exemplified by compound CM1012-6a with an IC50 value of 180 nM against the 
terminase nuclease domain but no effect against HSV-1 at 5 μM [44, 45]. Alternatively, potent 
anti-HSV αHTs have poor to fair anti-terminase activity. The IC50 value of compound RM-YM-
3-0613 is ~50 μM against the viral terminase, but was found to be a potent anti-HSV compound 
with an EC50 of 180 nM [44, 45]. Although αHTs were found to have anti-terminase activity in 





CHAPTER 3: MATERIALS AND METHODS 
3.1. Compound Selection 
Three αHTs, numbered 106, 111, and 115, were synthesized and provided by RP Murelli; 
the compounds were synthesized from kojic acid as previously described [125-127]. The 
chemical structures of each compound and previously reported anti-herpesviral activity are 
shown in Figure 1 and Table 3, respectively. All compounds were dissolved in DMSO, 
aliquoted, and stored at -20°C.  
3.2. Cells and Viruses 
African green monkey kidney epithelial cells (CV-1) and bovine kidney epithelial cells 
(MDBK) were maintained in DMEM growth medium containing 10% newborn calf serum and 
100 IU/ml penicillin-0.1 mg/ml streptomycin. Crandell Feline kidney epithelial cells (CRFK) 
were maintained in DMEM growth medium containing 10% fetal bovine serum and 100 IU/ml 
penicillin-0.1 mg/ml streptomycin. The following strains of viruses were used: HSV-1 wild-type 
strain F, BoHV-1 wild-type Cooper strain, EHV-1 strain 10N0148, and FHV-1 strain FH2CS. 
Virus stocks were grown and titered in permissive cell lines, including CV-1 for HSV-1, MDBK 
for BoHV-1 and EHV-1, and CRFK for FHV-1. All virus and cell stocks were stored in -80°C.   
3.3. Cytotoxicity Assay 
One mammalian cell line, MDBK cells, served as a representative sample. MDBK cells 
were seeded into 12-well plates and incubated in DMEM growth medium as previously 
described until 80% confluency was reached (~24 hours). The following concentrations of each 
αHT compound were used: 100 μM, 125 μM, 150 μM, and 175 μM. These concentrations were 
added to 1 mL of growth medium and applied to the cells in duplicate. The cytotoxic agent 
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sodium azide (Sigma-Aldrich) was added to one well (in duplicate) at 300 μM to serve as a 
positive control. DMSO at the highest dilution percentage served as the negative control. After 
24 hour incubation, 200 μL of a tetrazolium compound [3-(4,5-dimethyl-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] and an electron coupling reagent 
(phenazine ethosulfate; PES) (Promega) were added to each well with an additional 2 hour 
incubation. The absorbance at 490 nm was recorded and the survival rate was calculated, using 
the following equation: Absorbance sample/Absorbance control x 100. The 50% cytotoxic 
concentration values were calculated using GraphPad Prism. The concentrations of the 
compounds were log transformed. Non-linear regression, via log (inhibitor)-versus- response 
algorithm, was employed to determine the 50% cytotoxic concentration. 
3.4. HSV-1, BoHV-1, EHV-1, and FHV-1 Replication Inhibition Assays 
HSV-1, BoHV-1, and FHV-1 were added to a permissive cell line (CV-1, MDBK, and 
CRFK, respectively) at a multiplicity of infection (MOI) of  0.01 for 1 hour. EHV-1 was added 
to a permissive cell line (MDBK) at MOI 0.1 for 1 hour.  After 1 hour viral adsorption, the virus-
inoculated medium was removed. The cells were washed once with PBS and replaced with 
DMEM containing either DMSO (at the highest dilution percent) or various concentrations of 
αHT ([10 μM to 50 μM] for compounds 106 and 111 and [2 to 10 μM] for compound 115) for an 
additional 47 hours.  At 48 hours post-infection, the cells were assessed by phase-contrast 
microscopy for cytopathic effect or toxicity. Samples were frozen at -80°C, thawed, removed 
from the dish by scraping, and sonicated to release intracellular virus.  Infectious virus was 
measured by plaque assay on permissive cells. The 50% inhibitory concentration values were 
calculated using GraphPad Prism. The concentrations of each compound were log transformed, 
and the inhibitory activity was normalized with the bottom value set to 0. Non-linear regression, 
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using a log (inhibitor)-versus-normalized response algorithm was employed to determine 50% 
inhibitory concentration.  
3.5. Transmission Electron Microscopy 
BoHV-1 was added at MOI 1.0 to a  ~90% confluent monolayer of MDBK cells in a 6-
well plate for 1 hour incubation. After 1 hour, the virus-inoculum was removed and replaced 
with DMEM containing one of  the following: DMSO (at the highest dilution percent), 50 μM 
αHT-106, or 8 μM αHT-115 for an additional 13 hour incubation. The cells were then fixed, 
dehydrated, embedded, and thin sections were visualized by transmission electron microscopy as 
previously described [128]. 
3.6. Immunoblotting 
CV1 cells in 6-well plates were infected for 1 hour with HSV-1 at an MOI of 5.0; virus-
inoculated medium was removed and replaced with DMEM containing either DMSO (at the 
highest dilution percent), or DMSO solublized 50 μM αHT-106, 30 μM αHT-111, or 8 μM αHT-
115 for an additional 5 or 17 hours. The cells were then washed with PBS and solubilized in SDS 
sample buffer. The solubilized proteins were separated on 12% SDS polyacrylamide gels and 
transferred to nitrocellulose membranes. The 6 hour samples were probed with a monocolonal 
antibody (mAb) to ICP 27 (diluted 1:1,000 in PBS plus 1% BSA), while the 18 hour samples 
were probed with a mAb directed against glycoprotein C (gC) that was diluted 1:2,000 in PBS 
with 1% BSA. The bound antibodies were detected by incubating with anti-mouse 
immunoglobulin conjugated with horseradish peroxidase (HRP) and visualized by enhanced 
chemiluminescence (ECL; Amersham). For a loading control, the blot was stripped and reprobed 
with anti-actin antibodies (diluted 1:1000) and developed similarly. 
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3.7. Real-Time Quantitative PCR 
CV1 cells were infected with HSV-1(F) at an MOI of 5.0. After 1 hour incubation, the 
virus inoculated medium was removed and replaced with a DMSO vehicle control, 50 μM αHT-
106, 30 μM αHT-111, or 8 μM αHT-115. The samples were incubated for an additional 12 hours 
until DNA extraction (DNeasy). Target primers for UL51 (forward: 5’-GCC AGT CGT TCT 
AGG TTC AC-3’ and reverse: 5’-GTT AAC GCG CTA CTT CCC G-3’) were used to measure 
DNA replication, and the assay was performed with SYBR green (Thermo Scientific, Pittsburgh, 
PA) according to the manufacturer's directions. Briefly, reactions were performed with a volume 
of 20 μl, consisting of 50 ng of DNA template, 100 nM of each primer, 7.6 μl H2O, and 10 μl 
SYBR green mix. The thermal cycling protocol included an initial denaturation for 3 min at 
95°C and 35 cycles consisting of a denaturation step at 95°C for 10 s and an annealing step at 
60°C for 30 s. Each sample was analyzed in triplicate, and average threshold cycle (CT) values 
were used for further analysis.  
3.8. Southern Blotting 
Five 100-mm plates of CV1 cells, one of which was pre-treated with 300 μg/mL of 
phosphonoacetic acid (PAA; Sigma Aldrich) for 30 minutes, were infected with HSV-1 (F) at an 
MOI of 5.0; one 100-mm plate was infected with UL15-null virus at an MOI of 5.0. After the 1 
hour incubation, virus inoculation media was removed and replaced with DMSO vehicle control 
(HSV-1 and UL15-null), 300 μg/mL PAA, 50 μM αHT-106, 30 μM αHT-111, or 8 μM αHT-115. 
After an additional 17 hour incubation, the medium was removed and the cells were washed with 
phosphate-buffered saline (PBS), scraped, and pelleted by centrifugation at 1,000 x g for 5 
minutes. The cells were lysed, and total cellular DNA was extracted as described previously 
described [129]. Total DNA (~10 μg) was digested with BamHI, separated on 0.8% agarose gel 
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via electrophoresis, followed by denaturization in 1 M NaOH, neutralization in Tris buffer.  The 
denatured DNA was transferred to a nylon membrane by capillary action, and the transferred 
DNA was hybridized with [32P]dCTP-labeled BamHI P fragment of HSV-1(F) DNA. The bound 
probe was visualized by exposure to X-ray film with intensifying screens at −80°C.   
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CHAPTER 4: RESULTS 
4.1. Compound selection 
Three synthetic αHTs were selected that have varying potencies against the nuclease 
domain of the viral terminase as determined by an in vitro dual-probe fluorescence assay [45]. 
The anti-HSV activity of these three αHTs was also previously evaluated [44]. The in vitro anti-
terminase and in vivo anti-HSV potencies of the compounds were found to be discordant. The 
chemical structure and pharmacologic properties of the three selected compounds are detailed in 
Figure 1 and Table 3, respectively.  
 
 
















106 CM1012-6a 0.18 Full suppression at 50 NA [44, 45] 
111 CM1012-6f 5.6 Full suppression at 5 >50 [44, 45] 
115 RM-YM-3-0613 49.1 EC50 = 0.18  >100  [44, 45] 




4.2. αHTs are minimally toxic in mammalian cell lines 
The cytotoxicity of the three αHTs was assessed on MDBK cells using a cell proliferation 
assay. The three compounds showed minimal cytotoxicity at 24 hours with 50% cytotoxic 
concentration values exceeding 100 μM (Table 4).  
 
Table 4. CC50 values of αHT-106, -111, and -115 on MDBK cells. 





4.3. αHTs broadly suppress herpesviral replication inhibition 
Replication inhibition activity of αHTs was initially assessed with BoHV-1 at 
concentrations of 0.1, 1, 10 and 50 μM for αHT-106, -111 and -115. The viral titers, determined 
by plaque assay, were then compared to the DMSO-treated control. Complete inhibition was 
noted between concentrations of 10 and 50 μM for αHT-106 and -111 and between 1 and 10 μM 
for αHT-115, indicating increased potency of αHT-115. Given this initial data, replication 
inhibition was then assessed for HSV-1, BoHV-1, EHV-1, and FHV-1 using 10 and 50 μM of 
αHT-106 and -111 and 2 and 10 μM of αHT-115. For each virus, minimal suppression (an 
average of one log10 decrease) of viral replication was observed at the low αHT concentration (2 
and 10 μM) with marked suppression (an average of five log10 decrease) at the higher αHT 




Figure 2. Replication inhibition of HSV-1, BoHV-1, EHV-1, and FHV-1 by αHTs. 
 Relative to the control, there is marked suppression of viral replication at the higher 
concentrations 10 (αHT-115) and 50 μM  (αHT-106 and -111) and minimal inhibition at the 
lower concentrations 2 (αHT-115) and 10 μM (αHT-106 and -111).  The asterisks indicate that 
the titer is equivalent to the control. 
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4.4. αHT-115 has  more potent anti-herpesviral activity than αHT-106 and -111 
In order to calculate the 50% inhibitory concentration of each compound, additional 
replication inhibition assays were performed with αHT concentrations of 10, 20, 30, 40, and 50 
μM (αHT-106 and -111) and 2, 4, 6, 8, 10 μM (αHT-115). The 50% inhibitory concentration 
values were similar between αHT-106 and -111 at around  20 μM.  In contrast, αHT-115 was  
markedly more potent with an IC50 ranging between 1.5 and 5 μM. Thus, αHT-115 has more 
potent anti-herpesviral replication inhibition activity than αHT-106 and -111.  
 
Table 5. IC50 values of αHT-106, -111, and -115 with HSV-1, BoHV-1, FHV-1, and EHV-1. 





μM HSV-1 BoHV-1 FHV-1 EHV-1 
0 6.98 8.59 5.97 4.06 
10 6.34 7.76 4.60 4.59 
20 5.32 6.63 3.20 4.60 
30 4.62 5.34 2.00 3.48 
40 4.36 3.96 1.48 3.24 
50 3.58 2.83 2.00 2.64 
IC50 μM 20 26 15 30 
      
αHT-111 
μM HSV-1 BoHV-1 FHV-1 EHV-1 
0 6.28 6.12 6.18 4.02 
10 4.54 5.65 5.04 4.13 
20 2.00 2.70 3.38 3.66 
30 2.73 0.00 3.69 3.20 
40 1.00 0.00 3.00 3.19 
50 1.48 0.00 2.84 2.92 
IC50 μM 13 20 13 23 
 
     
αHT-115 
μM HSV-1 BoHV-1 FHV-1 EHV-1 
0 7.00 6.00 5.23 3.70 
2 4.00 5.64 3.85 4.20 
4 2.30 3.88 3.41 3.80 
6 2.30 2.78 3.08 3.10 
8 0.00 0.00 - 2.60 
10 0.00 0.00 - 2.80 
IC50 μM 2.2 5.0 1.5* 5.0 
34 
 
Table 6. Therapeutic indices for αHTs against HSV-1, BoHV-1, FHV-1, and EHV-1. 
Compound HSV-1 BoHV-1 FHV-1 EHV-1 
αHT-106 7.2 5.5 9.6 4.8 
αHT-111 9.9 6.5 9.9 5.6 
αHT-115 85.0 37.4 124.7 37.4 
 
 Based on the therapeutic indices (Table 6), αHT-115 had the highest therapeutic range, 
particularly for HSV-1 and FHV-1, while the indices of αHT-106 and  αHT-111 were at least 
six-fold lower (Table 6).   
 
4.5. αHTs decrease production of infectious progeny 
Transmission electron microscopy (TEM) was employed to assess virion development in 
the presence of αHTs. MDBK cells were infected with BoHV-1, in  the presence of a DMSO 
vehicle control, 50 μM αHT-106, or  8 μM αHT-115. Given that αHT-111 is considered an 
intermediate anti-herpesviral and anti-terminase compound, this compound was excluded. 
Numerous virions and C capsids were observed in the DMSO control BoHV-1 sample (Figure 
3). Application of both αHT-106 and -115 resulted in a marked decrease in extracellular viral 
particles and intranuclear capsids (Figure 4 and 5). A very rare small cluster of intranuclear 
electron-dense round structures was observed in  αHT-115 treated cells and is of unknown 
significance (Figure 6). The decrease in virion number further supports the compounds’ anti-









Figure 3. TEM of MDBK cells inoculated with BoHV-1 and treated with DMSO control. 














Figure 4. TEM of MDBK cells inoculated with BoHV-1 and treated with 50 μM αHT-106.  














Figure 5. TEM of MDBK cells inoculated with BoHV-1 and treated with 8 μM αHT-115.  
No virions or capsids are observed. Three large, round electron dense structures represent 





Figure 6. TEM of MDBK cells inoculated with BoHV-1 and treated with 8 μM αHT-115. 




4.6. αHTs inhibit expression of true late (γ2) proteins 
   To further elucidate the mechanism of action of αHTs, immunoblotting was performed to 
assess immediate-early (α, represented by ICP27) and late (γ2, represented by gC) protein 
expression in the presence of αHTs. CV1 cells were inoculated with wild-type HSV-1 and 
treated with a DMSO vehicle control, 50 μM αHT-106, 30 μM αHT-111, or 8 μM αHT-115. No 
change in immediate-early expression was noted between the DMSO control or drug treated 
samples (Figure 7A). However, compared to the wild-type HSV-1 control, there was decreased 
gC  expression in the αHT-treated samples.  The decrease in protein expression was more 
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marked in cells treated with αHT-115 and αHT-111 than αHT-106, and thus mirrored the relative 
antiviral potencies of these compounds (Figure 7B). These findings indicate that the effects on 
protein expression occurred between the expression of immediate-early proteins and that of late 




Figure 7. Immunoblotting of α (A) and γ (B) protein in αHT-treated HSV-1 samples. 
(A). There is no change in immediate-early protein expression compared to the HSV-1 wild-type 
control. β-actin, loading control. (B). There is decreased late protein expression in the αHT-
treated samples relative to the wild-type HSV-1 control, and the effect is potentiated by the 
increased potency of the compounds. β-actin, loading control. 
 
 
4.7. αHTs inhibit DNA replication 
To evaluate whether HTs affected DNA replication, HSV-1 viral DNA produced in the 
presence or absence of drug was measured by qPCR using UL51 specific probe and primers. 
Significant decreases in HSV-1 viral load were observed in αHT-treated samples (50 μM αHT-
106, 30 μM αHT-111, or 8 μM αHT-115) compared to wild-type HSV-1 control (p < 0.05) 
(Figure 8). Specifically, there was ~72 to 93% reduction in the amount of UL51 target sequences 
in αHT-treated samples compared to the DMSO treated control. Based on Tukey’s post-hoc 
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analysis, no significant differences were observed between samples treated with different drugs 
at the concentrations tested. Nevertheless, these data indicate that αHTs inhibit HSV-1 DNA 




Figure 8. Real-time qPCR of viral DNA in wild-type HSV-1 control and αHT-treated samples. 
The decrease in HSV-1 DNA copy number is significant, as determined by one-way ANOVA 
and Tukey’s post-hoc analysis (*, p < 0.05). No significant differences were observed between 
treated samples (50 μM αHT-106, 30 μM αHT-111, or 8 μM αHT-115). 
 
 
4.8. Attempted assessment of viral cleavage activity in the presence of αHT  
Previous research has shown that the αHTs, inhibit nuclease activity of pUL15C to varying 
extents using an in vitro dual-probe fluorescence assay. Specifically, αHT-106 was found to be 
more potent than αHT-111, and the effect of αHT-115 was negligible (Table 3) [45]. Although 
the results of immunoblotting and qPCR shown above indicated inhibition of viral DNA 
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replication, a concurrent effect on cleavage via inhibition of the viral terminase could not be 
excluded.  
To assess DNA cleavage in the presence and absence of drug treatment, CV1 cells were 
infected with HSV-1(F) and UL15-null. HSV-1(F) infected CV1 cells in the presence of  PAA (a 
known viral DNA synthesis inhibitor), αHT-106, αHT-111, αHT-115, or a DMSO vehicle-
control. Viral DNA was digested with a restriction enzyme (BamHI), separated 
electrophoretically, and probed with a radiolabeled terminus of the short component (P 
fragment). In Figure 9, the junctional S-P fragments can be observed in all samples. HSV-1(F) 
generated a broad P fragment. In the PAA, sample, low levels of DNA were detected and likely 
represented DNA from virions adsorbed to the cells (input DNA). As expected, the UL15-null 
virus failed to generate a short genomic segment. DNA levels in cells infected in the presence of 
the three αHTs were comparable to the PAA control, suggesting that the drugs conferred a  
marked inhibition of  viral DNA replication.. However, the levels of DNA in cells treated with 
the αHTs were too low to permit meaningful comparison between levels of terminal fragments 
and the junction fragments, which is a metric necessary to assess DNA cleavage in vivo.  Thus, 
the ability to verify the previous in vitro findings of anti-terminase activity of αHTs was 






Figure 9. Fluorographic image of viral DNA probed with radiolabeled terminus of the short 
component (P fragment).  
CV1 cells were infected with HSV-1(F) or UL15-null. The HSV-1(F) infected samples were 
treated with PAA, αHT-106, αHT-111, αHT-115 or DMSO vehicle-control. The positions of the 
S-P junctional fragment and BamHI P fragment are indicated. Decreased bands in the junctional 
and short fragments are noted in the αHT-treated samples and are comparable in level to that of 




CHAPTER 5: DISCUSSION 
The presented research shows that αHTs are broad anti-herpesviral compounds that act 
primarily at the level of viral DNA synthesis. αHTs were previously documented to inhibit HSV-
1 and -2 replication in vivo and postulated targets include viral proteins with an RNase H-like 
domain [43, 44]. In HSV-1, these targets include DNA polymerase (pUL30), single-stranded 
DNA binding protein (ICP8, pUL29), alkaline nuclease (pUL12) and the nuclease domain of the 
viral terminase (pUL15C) [37-42].  
αHTs were previously found to inhibit the nuclease domain of the viral terminase in vitro 
via a dual-probe fluorescence assay. Twenty-one synthetic αHTs were screened and variable 
potencies were documented, and the potencies were found to negatively correlate to the 
bulkiness of their modified side chain [45]. Interestingly, the αHTs with potent inhibition of viral 
replication were relatively poor inhibitors of pUL15C nuclease activity suggesting other HSV 
targets were being inhibited [44, 45].  
The three αHTs selected for this research had variable in vitro potencies against pUL15C, 
ranging from negligible (αHT-115), intermediate (αHT-111), to marked (αHT-106). These 
compounds were screened for activity against three important veterinary herpesviruses, BoHV-1, 
EHV-1, and FHV-1 and were also screened for activity against HSV-1 as a control. Each 
compound was found to be non-toxic with a 50% cytotoxic concentration value >100 μM, based 
on a cell proliferation assay performed on MDBK cells. The results of the replication inhibition 
assays were comparable across the different herpesviruses for each compound. Specifically, the 
50% inhibitory concentration values ranged from 15-30 μM for αHT-106, 13-23 μM for αHT-
111, and 1.5-5 μM for αHT-115 for the different viruses.  
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The relative potencies of these three αHTs are comparable to the previous observations 
against HSV-1 and -2 [44]. αHT-115 had the widest therapeutic range, with indices that ranged 
from 37 to 124. In contrast, the therapeutic indices for αHT-106 and αHT-111 were narrow, 
ranging from 4.8 to 9.6 and 5.6 to 9.9, respectively. Given there are no other differences between 
these compounds we conclude that αHT-115’s biaryl side chain optimized its inhibitory effect 
[44]. It is unclear why the addition of a biaryl side chain enhances anti-viral activity. Previous 
evaluation of synthetic αHT activity against Hepatitis B Viral RNase H showed markedly 
decreased to diminished effect as the modified side chains became longer [130]. However, 
similar to the research presented here, a previous study found that the relative potencies of two 
synthetic αHT compounds with biaryl side chains against HSV-1 and -2 were greater compared 
to αHT with alternate (including smaller) chemical modifications [44].  Thus, it is possible the 
addition of a biaryl appendage either enhances the binding with an enzyme’s active site or 
negates unfavorable interactions.   
To further elucidate the mechanism of action of αHTs against herpesviruses, the effect of 
αHTs against HSV-1 was assessed with transmission electron microscopy, immunoblotting, real-
time qPCR, and southern blotting. The results of these findings were consistent with inhibition of 
viral DNA replication. Specifically, production of capsids and infectious progeny depend upon 
optimal DNA synthesis, explaining the decreased virions and capsids in the αHT-treated samples 
relative to the DMSO-treated control as viewed by electron microscopy. Similarly, despite 
similar levels of immediate-early protein production in the presence of the compounds, we 
observed decreased DNA replication dependent true-late (γ2) protein expression in the αHT-
treated samples. The results of qPCR confirmed HSV-1 DNA replication inhibition by αHTs, as 
there was an approximately 72-93% decrease in UL51 target sequences in cells treated with αHT 
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compared to the wild-type control. Although the profound decrease in viral DNA synthesis 
precluded assessment of viral DNA cleavage we cannot exclude an additional effect on 
terminase activity of these compounds in vivo.  
Taken together, these data show that αHTs are broad, non-toxic compounds that 
primarily target herpesviral DNA replication. As αHTs have potent chelating ability due to the 
arrangement of three oxygen compounds, inhibition of cation-dependent enzyme(s) is likely 
[123]. As previously discussed, enzymes with RNase H-like domains require metal binding in 
their active sites. HSV-1 enzymes that function in DNA replication with RNase H activity 
include DNA polymerase (pUL30), single-stranded DNA binding protein (ICP8, pUL29), and the 
alkaline nuclease (pUL12) [37, 38, 40-42]. Due to their importance, these enzymes are highly 
conserved across Herpesviridae, a conclusion that is supported by the broad effects of αHTs 
presented in this study.  
Although, αHTs were previously reported to have anti-terminase activity, inhibition of 
viral DNA cleavage could not be confirmed. The previous in vitro study assessing the nuclease 
activity of pUL15 was performed with the addition of short DNA duplexes, thereby countering 
the inhibitory effect on DNA replication by the compounds [45]. In this study, evaluation of 
cleavage activity was precluded by the inability of herpesviruses to synthesize sufficient DNA in 
the presence of αHTs. Although not verified in this study, a concurrent inhibitory effect on the 
nuclease domain of the viral terminase or other RNase H-like HSV-1 enzyme is possible.  
It is unclear why the compounds showed similar, but reverse potencies with the in vitro 
anti-pUL15C assay and in vivo HSV-1 replication inhibition. As the in vitro anti-pUL15C 
activities were performed with supplemented DNA, it is possible that αHTs with different side 
chains have alternate anti-herpesviral effects. Of the three αHTs, αHT-106 had diverging results 
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with greater γ2 protein expression and larger suppression of DNA copy number relative to αHT-
111 and -115. Although Tukey’s post-hoc analysis did not yield a statistically significant 
difference between the αHT-treated samples, the possibility of additional targets by αHT-106 
cannot be excluded. Nonetheless, although some αHT compounds have negligible potency 
against pUL15C based on a dual-probe fluorescent assay (i.e., αHT-115), the effect of this 
compound against HSV-1 replication in vivo was impressive with IC50 ranging from 1.5-5 μM, 
which falls into the ideal potency range for pharmaceutical development [131].  
The activity of αHTs, specifically αHT-115, appears to rival those anti-herpesviral 
compounds currently available on the market. Although not directly compared in this study, the 
reported IC50 concentrations of acyclovir against HSV-1 range between 0.08 to 55 µM [132]. 
Additionally, as previous research has shown that αHTs suppress replication of acyclovir-
resistant HSV-1 and -2 mutants, these compounds appear to have a different mechanism of 
action than acyclovir and do not require phosphorylation by viral thymidine kinase for activation 
[43]. Kinase-independence is a potentially important attribute of these compounds, as viral 
resistance to nucleoside analogues is thought to occur through acquired mutations in the viral 
thymidine kinase. However, as mutations in the DNA polymerase have also been documented, 
determination of the exact mechanism of action of these compounds is critical [96, 97].  
Although anti-viral therapy is of limited in use in veterinary medicine, research has 
shown promising response with nucleoside analogue therapy in FHV-1 infected cats [16, 17, 24]. 
Specifically, IC50s for the following compounds were calculated in vitro against FHV-1: 4.3 µM 
for idoxuridine, 5.2 µM for ganciclovir, 11 µM for cidofovir, 58 µM for acyclovir, and 233 µM 
for foscarnet [133]. Thus, αHT-115, which has a partial IC50 of 1.5 against FHV-1, may serve as 
a promising compound for use in FHV-1 infected cats.    
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One limitation of this research includes the exclusive use of alphaherpesviruses. 
However, suppression of viral replication by αHTs with HCMV, a betaherpesvirus, has 
previously been performed, and the inhibition by αHTs was comparative to HSV-1 [43]. Given 
the well-conserved nature of core genes, it is likely that these compounds would inhibit 
herpesviruses in each subfamily.   
In conclusion, αHTs inhibit DNA replication and may comprise effective therapeutic 
agents against different species of herpesviruses. As certain synthetic αHT compounds have 
higher therapeutic indices compared to others, further optimization of therapeutic activity by 
alteration of the chemical side chains is worth testing.  Additional studies are recommended to 
further evaluate the efficacy of these compounds, including the genomic evaluation of escape 
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